Hepatocellular Carcinoma Clinical Trials

There are 38 registered clinical trials for Hepatocellular Carcinoma in the TrialLens index.

Trials (38)

• Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2 · Jules Bordet Institute
• A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma N/A · University of Aarhus
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) Phase 2 · University College, London
• Prophylactic Antibiotics Before RFA for HCC Phase 4 · Taipei Veterans General Hospital, Taiwan
• Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC N/A · Tongji Hospital
• to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) Phase 2 · Samsung Medical Center
• Study of Hepatocellular Carcinoma in Cirrhotic Patients N/A · Centre Hospitalier Universitaire Dijon
• TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study Phase 2 · Fei Gao
• the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma N/A · Second Affiliated Hospital, Zhejiang University, School of Medicine
• Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) Phase 3 · Singapore General Hospital
• Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma Phase 4 · Ain Shams University
• Nivolumab Combined With BMS-986253 in HCC Patients Phase 2 · NYU Langone Health
• Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma Phase 2 · Tiziana Life Sciences LTD
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma Phase 2 · The First Affiliated Hospital with Nanjing Medical University
• HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC Phase 3 · Sun Yat-sen University
• Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC Phase 2 · Zhejiang University
• SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist N/A · The University of Hong Kong
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors Phase 2 · Telix Pharmaceuticals (Innovations) Pty Ltd
• A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers N/A · National Taiwan University Hospital
• Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence N/A · TCM Biotech International Corp.
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC Phase 2 · Sun Yat-sen University
• Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection Phase 2/3 · Shanghai Junshi Bioscience Co., Ltd.
• A Study of Anlotinib in Patients With Hepatocellular Carcinoma Phase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma Phase 1 · Fukushima Medical University
• Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Phase 2 · Seoul National University Hospital
• A Comparison Between Child-Pugh and Albumin-Bilirubin Scores N/A · Huazhong University of Science and Technology
• Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients N/A · Taipei Veterans General Hospital, Taiwan
• Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Early Phase 1 · Ashwin Somasundaram
• A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Phase 1 · Human Genome Sciences Inc., a GSK Company
• Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) Phase 1/2 · Singapore Clinical Research Institute
• Extracellular RNA Markers of Liver Disease and Cancer N/A · Mayo Clinic
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial Phase 3 · Sun Yat-sen University
• A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT) N/A · University of Michigan Rogel Cancer Center
• TACE as an Adjuvant Therapy After Hepatectomy for HCC Phase 3 · Jia Fan
• Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients Phase 2 · The Methodist Hospital Research Institute
• Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE N/A · Seoul National University Hospital
• Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Phase 1/2 · VA Office of Research and Development
• HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial Phase 2 · Sun Yat-sen University

Related landscapes

• Phase 4 Hepatocellular Carcinoma
• Phase 1/2 Hepatocellular Carcinoma
• Phase 2 Hepatocellular Carcinoma
• Phase 3 Hepatocellular Carcinoma
• N/A Hepatocellular Carcinoma

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.